DXCM · Full Picture

DEXCOM INC — the full picture

Trailing window · 2026-05-11 to 2026-08-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 60
    +11.6% revenue (realized); quote_verified
    DexCom reported EPS of $0.70 and revenue of $1.31 billion, a 13.1% year-over-year increase.
  2. Competition and Market Share · Competition & market sharePriority 40
    quote_verified
    Tandem reaffirmed full-year 2026 financial guidance for sales between $1.065 billion and $1.085 billion.
  3. Litigation and Legal Risk · Litigation & settlementsPriority 32
    1 forward row(s); quote_verified
    Levi & Korsinsky filed a securities class action against DexCom on behalf of investors who purchased securities between January 8, 2024 and September 17, 2025.

Threads by pillar

Revenue & Demand Priority 60 · 1 thread

Legal, Regulatory & Policy Priority 32 · 1 thread

Macro & Market Conditions Priority 40 · 1 thread

Expected impact by metric

metricforward netforward grossrealized
revenue——+11.6%